Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.60 |
| ▸ | HTR6 | P50406 | 3/20 | 0.60 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3652029 | 0.88 | HTR2A (0.46) | HTR2AHTR6GRM5HTR1ADRD2 | |
| SCHEMBL19327019 | 0.86 | HTR2A (0.62) | HTR2AHTR6GRM5HTR1ADRD2 | |
| SCHEMBL951404 | 0.86 | HTR6 (0.56) | HTR2AHTR6HTR1ADRD2HTR7 | |
| SCHEMBL2198404 | 0.84 | HTR2A (0.60) | HTR2AHTR6GRM5HTR1ADRD2 | |
| SCHEMBL3208018 | 0.84 | HTR2A (0.60) | HTR2AHTR6GRM5HTR1ADRD2 | |
| SCHEMBL949595 | 0.84 | HTR2A (0.44) | HTR2AHTR6HTR1ADRD2HTR7 | |
| SCHEMBL2196768 | 0.83 | SLC40A1 (0.46) | HTR2AHTR6HTR1ADRD2HTR7 | |
| SCHEMBL2195845 | 0.81 | HTR2A (0.56) | HTR2AHTR6GRM5HTR1ADRD2 | |
| SCHEMBL3650523 | 0.80 | SLC40A1 (0.48) | HTR2AHTR6HTR1ADRD2HTR7 | |
| SCHEMBL18796178 | 0.79 | HTR2A (0.54) | HTR2AHTR6GRM5NFE2L2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135777-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-05-09 | — | — | US | disclosed |
| US-10160744-B2 | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-12-25 | — | — | US | disclosed |
| WO-2017157929-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-09-21 | — | — | WO | disclosed |
| US-20170260158-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-09-14 | — | — | US | disclosed |
| EP-2185555-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8440694-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20130005703-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN-5-HT6 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8293913-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8236947-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-1956004-B1 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | disclosed |
| US-20100292271-A1 | Quinoline Compounds Suitable for Treating Disorders that Respond to Modulation of the Serotonin-5-HT6 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-7799774-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| EP-2185555-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-05-19 | — | — | EP | disclosed |
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| WO-2009019286-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-02-12 | — | — | WO | disclosed |
| US-20090036682-A1 | Quinoline Derivatives and Their Use as 5-HT6 Ligands | GLAXO GROUP LIMITED | 2009-02-05 | — | — | US | disclosed |
| EP-1956004-A1 | Quinoline derivatives and their use as 5-HT6 ligands | Glaxo Group Limited (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20050124628-A1 | Novel compounds | ROIVANT NEUROSCIENCES LTD. (BM) | 2005-06-09 | — | — | US | disclosed |
| EP-1497266-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080580-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR3B, HTR4 | HTR2A 9/4885HTR6 1/4885GRM5 40/4885 |
| US-20050124628-A1 | Novel compounds | NLN, ATP6V1B2, CHRNA2 | HTR2A 124/4885HTR6 111/4885GRM5 33/4885 |
| US-20100292271-A1 | Quinoline Compounds Suitable for Treating Disorders that Respond to Modulation of the Serotonin-5-HT6 Receptor | HTR6, HTR1A, HTR3B | HTR2A 7/4885HTR6 1/4885GRM5 189/4885 |
| US-20130005703-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN-5-HT6 RECEPTOR | HTR6, HTR1A, HTR3B | HTR2A 7/4885HTR6 1/4885GRM5 220/4885 |
| US-20170260158-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR5A, HTR1A | HTR2A 6/4885HTR6 1/4885GRM5 44/4885 |
| US-10160744-B2 | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor | HTR6, HTR5A, HTR1A | HTR2A 6/4885HTR6 1/4885GRM5 44/4885 |
| US-20090036682-A1 | Quinoline Derivatives and Their Use as 5-HT6 Ligands | HTR6, HTR3B, HTR4 | HTR2A 9/4885HTR6 1/4885GRM5 40/4885 |
| US-20190135777-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR5A, HTR1A | HTR2A 6/4885HTR6 1/4885GRM5 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.